GleamWall
中文EN

XBIO Xenetic Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1534525 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.5%
TTM net income YoY-16.0%
TTM EPS YoY24.0%
Revenue 3-yr CAGR7.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-129.6%
Net margin-123.7%
FCF margin—
EBITDA margin—

Returns

ROE-87.5%
ROA-64.3%
ROIC (approx.)—
Asset turnover0.52x

Leverage & solvency

Liabilities / assets30.1%
Debt / equity0.00x
Current ratio3.15x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.63x
Accruals ratio-23.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$725,257$660,601$806,923$766,296$1.03M$589,897$593,261$648,820
R&D expense$520,663$552,013$661,443$773,416$756,482$656,557$879,029$1.04M
SG&A expense$1.94M$1.08M$647,597$615,907$815,209$657,752$656,641$705,710
Operating income-$1.74M-$971,690-$502,117-$623,027-$544,734-$724,412-$942,409-$1.10M
Income tax$0$0$0$0$0$0$0$0
Net income-$1.70M-$929,695-$456,382-$579,076-$509,940-$688,703-$903,141-$1.05M
EPS (basic)-0.72-0.41-0.20—-0.33-0.45-0.59—
EPS (diluted)-0.72-0.41-0.20—-0.33-0.45-0.59—
Weighted avg. shares (diluted)2.34M2.29M2.29M—1.54M1.54M1.54M—
Banking
Net interest income———$43,792$30,783$34,232$39,190$51,867
Balance sheet
Cash & equivalents$5.81M$6.47M$7.35M$7.88M$4.12M$4.78M$5.16M$6.17M
Current assets$6.00M$6.65M$7.60M$8.05M$5.07M$5.35M$5.48M$6.59M
Total assets$6.32M$6.97M$7.91M$8.36M$5.07M$5.35M$5.79M$6.90M
Current liabilities$1.90M$894,977$958,239$968,025$1.11M$903,430$667,927$894,263
Total liabilities$1.90M$894,977$958,239$968,025$1.11M$903,430$667,927$894,263
Shareholders' equity$4.41M$6.07M$6.95M$7.40M$3.96M$4.45M$5.12M$6.01M
Shares outstanding2.34M2.34M2.29M2.29M1.54M1.54M1.54M1.54M
Cash flow statement
Operating cash flow-$662,131-$875,489-$536,377-$242,682-$658,247-$383,830-$1.00M-$673,992
Stock-based compensation$36,022$51,964$11,312$13,998$15,855$15,683$19,251$25,108

Free plan shows the latest 8 periods; Pro shows all 64 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.